España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Immix Biopharma
IMMX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.98
0.01
0.51%
At close: -
$1.96
-0.02
-1.01%
After Hours: 7:07 AM EDT
Get Report
Comment
Immix Biopharma (IMMX) Forecast
News
Earnings
Immix Biopharma (IMMX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Immix Biopharma (NASDAQ:IMMX) Stock
Immix Biopharma Stock (NASDAQ: IMMX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 07, 2025
Immix Biopharma Completes Phase 1b Safety Run...
Benzinga Newsdesk
Monday, January 06, 2025
HC Wainwright & Co. Reiterates Buy on Immix B...
Benzinga Newsdesk
Thursday, December 19, 2024
Immix Biopharma Announces Initial Data From F...
Benzinga Newsdesk
Monday, December 16, 2024
Immix Biopharma Publishes NXC-201 Clinical Re...
Benzinga Newsdesk
Tuesday, December 10, 2024
Immix Biopharma Reports 75% Complete Response...
Benzinga Newsdesk
Monday, November 25, 2024
Immix Biopharma Presents NXC-201 Clinical Dat...
Benzinga Newsdesk
Thursday, October 03, 2024
HC Wainwright & Co. Reiterates Buy on Immix B...
Benzinga Newsdesk
Wednesday, October 02, 2024
Immix Biopharma Reports CAR-T NXC-201 To Expa...
Benzinga Newsdesk
Wednesday, August 28, 2024
Immix Biopharma Expands U.S. Clinical Trial S...
Benzinga Newsdesk
Monday, August 19, 2024
HC Wainwright & Co. Reiterates Buy on Immix B...
Benzinga Newsdesk
Friday, July 26, 2024
HC Wainwright & Co. Reiterates Buy on Immix B...
Benzinga Newsdesk
Reported Earlier, Immix Biopharma Secures $8M...
Benzinga Newsdesk
Tuesday, July 09, 2024
HC Wainwright & Co. Reiterates Buy on Immix B...
Benzinga Newsdesk
Monday, July 08, 2024
Immix Biopharma Doses First Patient In U.S. A...
Benzinga Newsdesk
Monday, July 01, 2024
HC Wainwright & Co. Initiates Coverage On Imm...
Benzinga Newsdesk
Friday, May 10, 2024
Immix Biopharma Reports NXC-201 Relapsed/Refr...
Benzinga Newsdesk
Monday, April 29, 2024
Immix Biopharma Awarded European Union Orphan...
Benzinga Newsdesk
Thursday, April 18, 2024
Immix Biopharma On Track To Dose NXC-201 U.S....
Benzinga Newsdesk
Monday, April 15, 2024
Immix Biopharma Announces NXC-201 Clinical Da...
Benzinga Newsdesk
Wednesday, March 20, 2024
Immix Biopharma Announces Comprehensive Cance...
Benzinga Newsdesk
Wednesday, February 21, 2024
Immix Biopharma Announces 12-Month Progress U...
Benzinga Newsdesk
Wednesday, February 07, 2024
Immix Biopharma Awarded European Union Orphan...
Benzinga Newsdesk
Tuesday, February 06, 2024
Reported Late Monday, Immix Biopharma Prices ...
Benzinga Newsdesk
Monday, February 05, 2024
Immix Biopharma Shares Resume Trading
Benzinga Newsdesk
Immix Biopharma Shares Halted On Circuit Brea...
Benzinga Newsdesk
Immix Biopharma Shares Resume Trade
Benzinga Newsdesk
Immix Biopharma Shares Halted On Circuit Brea...
Benzinga Newsdesk
Immix Biopharma Announces Proposed Public Off...
Benzinga Newsdesk
Thursday, January 25, 2024
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Wednesday, January 24, 2024
Immix Biopharma Statement On Jan. 2024 FDA La...
Benzinga Newsdesk
Friday, December 15, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Thursday, December 14, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Monday, December 11, 2023
Immix Biopharma Announces 100% Overall Respon...
Benzinga Newsdesk
Tuesday, November 21, 2023
Immix Biopharma Announces FDA Approval Of IND...
Benzinga Newsdesk
Friday, November 10, 2023
CFO at Immix Biopharma Acquires Company Stock Options Worth 293,000 Shares
Benzinga Insights
Monday, November 06, 2023
Immix Biopharma shares are trading higher aft...
Benzinga Newsdesk
Immix Biopharma Presents NXC-201 Data At 65th...
Benzinga Newsdesk
Monday, October 23, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Monday, October 16, 2023
Immix Biopharma Completes 3rd NXC-201 Enginee...
Benzinga Newsdesk
Tuesday, October 03, 2023
Immix Biopharma Shares Halted On Circuit Brea...
Benzinga Newsdesk
Immix Biopharma Announces Complete Response I...
Benzinga Newsdesk
Monday, October 02, 2023
What's Going On With Cancer-Focused Immix Biopharma Stock Today?
Vandana Singh
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Immix Biopharma Announces 72-Patient NXC-201 ...
Benzinga Newsdesk
Monday, September 25, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Immix Biopharma Inc Files For Shelf Of Up To ...
Benzinga Newsdesk
Thursday, September 21, 2023
U.S. Food And Drug Administration Approves Orphan Drug Designation For Immix Biopharma NXC-201 As A Treatment For Amyloid Light Chain Amyloidosis
Happy Mohamed
Tuesday, September 19, 2023
Director of Immix Biopharma Purchased $200K In Stock
Benzinga Insights
Immix Biopharma Subsidiary Nexcella Completes...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
